WAY-261240

WAY-261240
Identifiers
IUPAC name
  • [(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methanamine
PubChem CID
Chemical and physical data
FormulaC16H15Cl2NO
Molar mass308.20 g·mol−1
3D model (JSmol)
SMILES
  • C1CC2=C(C(=CC=C2)C3=C(C=CC=C3Cl)Cl)O[C@H]1CN
InChI
  • InChI=1S/C16H15Cl2NO/c17-13-5-2-6-14(18)15(13)12-4-1-3-10-7-8-11(9-19)20-16(10)12/h1-6,11H,7-9,19H2/t11-/m1/s1
  • Key:BNXPDLFCGJFNOG-LLVKDONJSA-N

WAY-261240 is a drug which acts as a potent and selective 5-HT2C receptor agonist, though its affinity at other serotonin receptors has not been disclosed. It produces anorectic effects in animal studies. A large family of related derivatives are known.[1][2][3][4][5][6]

See also

References

  1. ↑ Lee J, Jung ME, Lee J (November 2010). "5-HT2C receptor modulators: a patent survey". Expert Opinion on Therapeutic Patents. 20 (11): 1429–55. doi:10.1517/13543776.2010.518956. PMID 20849206. S2CID 32729624.
  2. ↑ WO 2006116165, Heffernan GD, Stack GP, Gross JL, Zhou D, Gao H, "Chromane and chromene derivatives and uses thereof", published 2 November 2006, assigned to Wyeth.
  3. ↑ WO 2005044812, Gross JL, Williams MJ, Stack GP, Gao H, Zhou D, "Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists", published 19 May 2005, assigned to Wyeth.
  4. ↑ WO 2006116158, Zhou D, Stack GP, Gross JL, Gao H, "Benzodioxane and benzodioxolane derivatives and uses thereof", published 2 November 2006, assigned to Wyeth.
  5. ↑ WO 2008052075, Stack GP, Hatzenbuhler NT, Zhou D, "Benzoxazine derivatives and uses thereof", published 2 May 2008, assigned to Wyeth.
  6. ↑ WO 2008052078, Stack GP, Luoni G, Bianchi I, Vallese S, "Benzoxathiine and benzoxathiole derivatives and uses thereof", published 2 May 2008, assigned to Wyeth.


This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.